KCT0000713招募中未知
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in combination with standard antiviral therapy in patients who have been treated with HB110E Hepatitis B DNA vaccine
Gegexine0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1. within 6 months of Hepatitis B DNA vaccine(HB110E) 2mg or 4mg administration
- •2. Chronic hepatitis B patients proved by positive HBsAg at screening
- •3. Serum HBV DNA level below 300 copies/mL at screening
- •4. ALT level within 2x ULN (40units/L) at screening
- •5. voluntarily provide the informed consent
排除标准
- •1. participation in other study within 30 days of screening
- •2. subjects with severe allergic reaction or severe adverse event to HBsAg vaccine, or not suitable for HBsAg vaccine
- •3. any other conditions that are considered inappropirate for the study by the investigator
研究者
相似试验
已完成
1 期
Comparison of the response to HBS Ag vaccine in chronic renal failure patients with different GFR levelsChronic renal failure.Chronic renal failureIRCT138803121267N8rology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C.( SBMU), Tehran, I.R.300
进行中（未招募）
不适用
A clinical trial to study the optimal dose of Hepatitis B vaccine in Human Immunodeficiency Virus (HIV) infected childreCTRI/2016/01/006495Shahid Akhtar Siddiqui60
Unknown
不适用
Study to evaluate immunogenicity of the hepatitis B antigen of the GSK Biologicals¿ candidate malaria vaccine (257049)Hepatitis BMalariaPACTR201104000284208GlaxoSmithKline Biologicals705
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005367-27-SKBIOVOMED
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vaccine or Pfizer’s 13-valent pneumococcal conjugate vaccine in the Czech Republic.To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005366-35-CZBIOVOMED